Clinical Trial

A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
Zimmer Biomet is prioritizing specific products within its portfolio and has chosen not to extend the CE mark for the GTS stem under MDR requirements, leading to the premature termination of the GTS study in 2024.
Summary
This is a multicenter, non-controlled, prospective study. 303 subjects (GTS standard and lateralized) have been recruited. Study will be conducted in centers across Europe.
Protocol Amendment History 4 changes
critical Trial terminated 2026-08-11
critical Trial terminated: Zimmer Biomet is prioritizing specific products within its portfolio and has chosen not to extend the CE mark for the G... 2026-08-11
notable Primary completion moved earlier: 2020-12 -> 2020-05 2026-08-11
minor Completion moved earlier: 2028-09 -> 2025-05 2026-08-11
Trial Details
NCT Number NCT02851992
Lead Sponsor Zimmer Biomet
Conditions Osteoarthritis, Hip
Enrollment 303 participants
Start Date 2012-09
Primary Completion 2020-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-10